RecruitingNCT06504927
Biomarker Discovery in Lung Cancer - Malaysia
Sponsor
University of Malaya
Enrollment
400 participants
Start Date
Jan 16, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
This study aims to 1. Identify biomarkers and signatures to differentiate between high-risk and lung cancer patients. 2. Discover blood-based biomarkers that can be used as an adjunct test to imaging diagnosis to improve patient follow-up.
Eligibility
Min Age: 30 Years
Plain Language Summary
Simplified for easier understanding
This study in Malaysia is looking for a blood-based biomarker — a measurable signal in the blood — that can help detect lung cancer at an early stage. It focuses on people who already have lung-related conditions (like COPD or small lung nodules) but have not been diagnosed with lung cancer, to see if a blood test can provide early warning.
**You may be eligible if...**
- You are 30 years or older
- You have no previous history of any cancer
- You have COPD or small lung nodules (under 11mm) that don't require biopsy
- You are willing to provide blood samples and return for follow-up scans
- You can provide your X-ray or low-dose CT (LDCT) scan results
**You may NOT be eligible if...**
- You have received chemotherapy, radiotherapy, or any cancer treatment
- You are pregnant or breastfeeding
- You are unwilling to sign consent
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06504927
Related Trials
Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients
NCT040386191 location
A Registry for People With Lung Cancer
NCT0642432718 locations
RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial
NCT0410527010 locations
Precision Navigation to Improve Community Cancer Screening Participation
NCT07676383
BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)
NCT07625644